{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:37Z","timestamp":1791497917525,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To what extent do drug approvals differ between Europe (EMA) and the USA (FDA) differ, and how do these differences arise? The study examines differences in approval timelines, therapeutic areas, mechanisms of action, and the marketing authorisation holders for the period between 2013 and 2023. All medicines containing a new active substance (NAS) from the European Medicines Agency\u2019s (EMA) Annual Reports, as well as all new molecular entities (NMEs) from the US Food and Drug Administration\u2019s (FDA) New Drug Therapy Approvals Reports and the annual Biological Approvals were assessed. The FDA authorised significantly more novel drugs (583) than the EMA (424) during the analysed period. The FDA granted far more exclusive drug approvals (185) than the EMA (42). Both agencies prioritise the therapeutic areas oncology, infectious diseases, haematology, and neurology. Enzyme inhibitors and antibodies are the most common drug classes. Pfizer, Novartis, and AstraZeneca are the Top-3 marketing authorisation holders (MAHs) for the FDA and EMA. The overall US share of EMA approvals exceeds the EU share of FDA approvals. The FDA also tends to use faster and more flexible approval pathways and shows greater tolerance for uncertainty in benefit-risk assessments. It also relies more frequently on surrogate endpoints and limited clinical data, particularly in accelerated approval pathways. In contrast, the EMA shows a stronger focus on long-term safety and public health priorities. Minor timing differences were observed, with the FDA generally authorising drugs earlier. These differences reflect not only company strategies and geographic patterns but also divergent regulatory processes due to different financial frameworks. The FDA also works with a broader range of MAHs overall, suggesting a more diverse and globally active company base. It also approves a wider variety of drugs, including more drugs with unknown mechanism of action. Various international initiatives aim to harmonise regulatory approaches and promote collaboration between agencies. Despite these efforts, differences remain, especially in response to urgent public health challenges. The FDA takes a more exploratory approach to drug approvals, whereas the EMA is more public health oriented. Differences in financial framework, decision-making processes, therapeutic priorities, geographical factors, and strategic marketing decisions of drug companies all contribute to the differences observed in this study. Efforts are in progress to globally harmonise drug approval processes.<\/jats:p>","DOI":"10.1007\/s00210-025-04412-4","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:06:05Z","timestamp":1751519165000},"page":"279-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of drug approvals of the FDA and EMA between 2013 and 2023"],"prefix":"10.1007","volume":"399","author":[{"given":"Franziska","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"4412_CR1","unstructured":"European Medicines Agency, US Food and Drug Administration (2021) General principles EMA-FDA parallel scientific advice (human medicinal products). https:\/\/www.ema.europa.eu\/en\/documents\/other\/general-principles-european-medicines-agency-food-and-drug-administration-parallel-scientific-advice_en.pdf. Accessed  2 Apr 2025"},{"key":"4412_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04020-2","author":"ZS Aksoyalp","year":"2025","unstructured":"Aksoyalp ZS, Kayki-Mutlu G, Wojnowski L, Michel MC (2025) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04020-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4412_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1200223","author":"NS Downing","year":"2012","unstructured":"Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS (2012) Regulatory review of novel therapeutics\u2013comparison of three regulatory agencies. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMsa1200223","journal-title":"N Engl J Med"},{"key":"4412_CR4","unstructured":"European Medicines Agency (2013) Kynamro EPAR public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kynamro-epar-public-assessment-report_en.pdf. Accessed  28 Mar 2025"},{"key":"4412_CR5","unstructured":"European Medicines Agency (2015a) Reflection paper on chemical structure and properties criteria to be considered in the evaluation of new active substance (NAS) status of chemical substances. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances_en.pdf. Accessed 6 Mar 2025"},{"key":"4412_CR6","unstructured":"European Medicines Agency (2015b) Annexes to the annual report of the European Medicines Agency 2014. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/annexes-annual-report-european-medicines-agency-2014_en.pdf. Accessed  10 Jan 2024"},{"key":"4412_CR7","unstructured":"European Medicines Agency (2018) Exondys EPAR refusal public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/exondys-epar-refusal-public-assessment-report_en.pdf. Accessed 3  Apr  2025"},{"key":"4412_CR8","unstructured":"European Medicines Agency (2019) From laboratory to patient: the journey of a centrally authorised medicine. https:\/\/www.ema.europa.eu\/en\/documents\/other\/laboratory-patient-journey-centrally-authorised-medicine_en.pdf. Accessed Mar 27, 2025"},{"key":"4412_CR9","unstructured":"European Medicines Agency (2020) 2019 annual report of the European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2019-annual-report-european-medicines-agency_en.pdf. Accessed  21 Nov 2023"},{"key":"4412_CR10","unstructured":"European Medicines Agency (2021a) Spikevax: EPAR product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-epar-product-information_en.pdf. Accessed  3 Nov 2023"},{"key":"4412_CR11","unstructured":"European Medicines Agency (2021b) Evrenzo: EPAR \u2013 public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/evrenzo-epar-public-assessment-report_en.pdf. Accessed  22 Mar 2025"},{"key":"4412_CR12","unstructured":"European Medicines Agency (2021c) Withdrawal assessment report: Aduhelm (aducanumab). https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-aduhelm_en.pdf. Accessed  25 Mar 2025"},{"key":"4412_CR13","unstructured":"European Medicines Agency (2021d) 2020 annual report of the European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2020-annual-report-european-medicines-agency_en.pdf. Accessed  7 Sept 2023"},{"key":"4412_CR14","unstructured":"European Medicines Agency (2022) 2021 annual report of the European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2021-annual-report-european-medicines-agency_en.pdf. Accessed  29 Oct 2023"},{"key":"4412_CR15","unstructured":"European Medicines Agency (2023) 2022 annual report of the European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2022-annual-report-european-medicines-agency_en.pdf. Accessed  17 Aug 2023"},{"key":"4412_CR16","unstructured":"European Medicines Agency (2024) Joint HMA\/EMA multi-stakeholder workshop report on submission predictability. https:\/\/www.ema.europa.eu\/system\/files\/documents\/report\/report-en.pdf. Accessed  30 Mar 2025"},{"key":"4412_CR17","unstructured":"European Medicines Agency (2025) Questions and answers on the approval of the marketing authorisation for Leqembi (lecanemab). https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-approval-marketing-authorisation-leqembi-lecanemab_en.pdf. Accessed 25 Mar 2025"},{"key":"4412_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9683016","author":"M Huber","year":"2019","unstructured":"Huber M, Huber B (2019) Innovation in oncology drug development. J Oncol. https:\/\/doi.org\/10.1155\/2019\/9683016","journal-title":"J Oncol"},{"key":"4412_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3434","author":"TJ Hwang","year":"2020","unstructured":"Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS (2020) Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ. https:\/\/doi.org\/10.1136\/bmj.m3434","journal-title":"BMJ"},{"key":"4412_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1565","author":"M Kashoki","year":"2020","unstructured":"Kashoki M, Hanaizi Z, Yordanova S, Vesel\u00fd R, Bouygues C, Llinares J, Kweder SL (2020) A comparison of EMA and FDA decisions for new drug marketing applications 2014\u20132016: concordance, discordance, and why. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.1565","journal-title":"Clin Pharmacol Ther"},{"key":"4412_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-021-02085-3","author":"G Kayki-Mutlu","year":"2021","unstructured":"Kayki-Mutlu G, Michel MC (2021) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-021-02085-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4412_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-022-02250-2","author":"G Kayki-Mutlu","year":"2022","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2022) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-022-02250-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4412_CR23","doi-asserted-by":"publisher","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2023) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn Schmiedebergs Arch Pharmacol.  https:\/\/doi.org\/10.1007\/s00210-023-02465-x","DOI":"10.1007\/s00210-023-02465-x"},{"key":"4412_CR24","doi-asserted-by":"publisher","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2024) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023. Naunyn Schmiedebergs Arch Pharmacol.  https:\/\/doi.org\/10.1007\/s00210-024-03063-1","DOI":"10.1007\/s00210-024-03063-1"},{"key":"4412_CR25","doi-asserted-by":"publisher","unstructured":"Lythgoe MP, Desai A, Gyawali B, Savage P, Krell J, Warner JL, Khaki AR (2022) Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010\u20132019. JAMA Netw Open.  https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16183","DOI":"10.1001\/jamanetworkopen.2022.16183"},{"key":"4412_CR26","doi-asserted-by":"publisher","unstructured":"Mitchell AP, Trivedi NU, Bach PB (2022) The Prescription Drug User Fee Act: much more than user fees. Med Care.  https:\/\/doi.org\/10.1097\/MLR.0000000000001692","DOI":"10.1097\/MLR.0000000000001692"},{"key":"4412_CR27","doi-asserted-by":"publisher","unstructured":"Papapetropoulos A, Topouzis S, Alexander SPH, Cortese-Krott M, Kendall DA, Martemyanov KA, Mauro C, Nagercoil N, Panettieri RAJ, Patel HH, Schulz R, Stefanska B, Stephens GJ, Teixeira MM, Vergnolle N, Wang X, Ferdinandy P (2024) Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.16337","DOI":"10.1111\/bph.16337"},{"key":"4412_CR28","unstructured":"European Union (2024) Regulation (EU) 2024\/568 of the European Parliament and of the Council of 7 February 2024 on fees and charges payable to the European Medicines Agency. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=OJ:L_202400568. Accessed  2 Apr 2025"},{"key":"4412_CR29","unstructured":"US Food and Drug Administration (2014) Novel new drugs 2013 summary. http:\/\/wayback.archive-it.org\/7993\/20161022200106\/http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DrugInnovation\/UCM381803.pdf. Accessed  5 Mar 2024"},{"key":"4412_CR30","unstructured":"US Food and Drug Administration (2017) New drug therapy approvals 2016. https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/new-drug-therapy-approvals-2016. Accessed  23 Feb 2024"},{"key":"4412_CR31","unstructured":"US Food and Drug Administration (2022a) Biologics license application approval letter for SPIKEVAX. https:\/\/www.fda.gov\/media\/155815\/download. Accessed  15 Mar 2025"},{"key":"4412_CR32","unstructured":"US Food and Drug Administration (2022b) Advancing health through innovation: new drug therapy approvals 2021. https:\/\/www.fda.gov\/media\/155227\/download. Accessed 6  Feb 2025"},{"key":"4412_CR33","unstructured":"US Food and Drug Administration (2024a) FDA at a glance October 2024. https:\/\/www.fda.gov\/media\/182749\/download. Accessed 28  Mar 2025"},{"key":"4412_CR34","unstructured":"US Food and Drug Administration (2024b) Advancing health through innovation: new drug therapy approvals 2023. https:\/\/www.fda.gov\/media\/175253\/download. Accessed  30 Sept 2024"},{"key":"4412_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2685","author":"KN Vokinger","year":"2022","unstructured":"Vokinger KN, Kesselheim AS, Glaus CEG, Hwang TJ (2022) Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021. JAMA Health Forum. https:\/\/doi.org\/10.1001\/jamahealthforum.2022.2685","journal-title":"JAMA Health Forum"},{"key":"4412_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069132","author":"J Xie","year":"2023","unstructured":"Xie J, Li J, Liu Y, Wang H, Wang Y, Yang Y, Chen Y, Jiang R, Shao R (2023) Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006\u20132021: a cross-sectional study. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2022-069132","journal-title":"BMJ Open"},{"key":"4412_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018587","author":"J Zeitoun","year":"2017","unstructured":"Zeitoun J, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P (2017) Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2017-018587","journal-title":"BMJ Open"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04412-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04412-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04412-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:49:27Z","timestamp":1771494567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04412-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4412"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04412-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      ) and officially registered as doctoral thesis project for Franziska Lau. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of the journal for editors acting as author (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}